162 related articles for article (PubMed ID: 36581339)
1. Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.
Li J; Cho YK; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
Cancer Genomics Proteomics; 2023; 20(1):9-17. PubMed ID: 36581339
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
[TBL] [Abstract][Full Text] [Related]
4. A Single Nucleotide Polymorphism (SNP) in the
Li J; Persaud AK; Johnson JA; Sborov DW; Phelps MA; Hofmeister CC; Poi MJ
Anticancer Res; 2022 Jan; 42(1):385-395. PubMed ID: 34969749
[TBL] [Abstract][Full Text] [Related]
5. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
6. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
[TBL] [Abstract][Full Text] [Related]
7. Genetic association in
Bellah SF; Salam MA; Billah SMS; Karim MR
Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
[TBL] [Abstract][Full Text] [Related]
8. The rs776746 variant of CYP3A5 is associated with intravenous midazolam plasma levels and higher clearance in critically ill Mexican paediatric patients.
Flores-Pérez C; Castillejos-López MJ; Chávez-Pacheco JL; Dávila-Borja VM; Flores-Pérez J; Zárate-Castañón P; Acosta-Bastidas M; Cruz-Escobar J; Torres-Espíndola LM
J Clin Pharm Ther; 2021 Jun; 46(3):633-639. PubMed ID: 33638195
[TBL] [Abstract][Full Text] [Related]
9. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.
Sanchez Spitman AB; Moes DJAR; Gelderblom H; Dezentje VO; Swen JJ; Guchelaar HJ
Eur J Clin Pharmacol; 2017 Dec; 73(12):1589-1598. PubMed ID: 28849250
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
[TBL] [Abstract][Full Text] [Related]
13. [Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study].
Moreno I; Quiñones L; Catalán J; Miranda C; Roco Á; Sasso J; Tamayo E; Cáceres D; Tchernitchin AN; Gaete L; Saavedra I
Biomedica; 2012; 32(4):570-7. PubMed ID: 23715232
[TBL] [Abstract][Full Text] [Related]
14. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
15. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
16. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
17. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
Zhang J; Dai Y; Liu Z; Zhang M; Li C; Chen D; Song H
Ther Drug Monit; 2017 Aug; 39(4):406-411. PubMed ID: 28700521
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
20. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
